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Sublobar Resection
Are the Answers Different or Is It the Questions?
Frank C. Detterbeck, MD
The review by Blasberg et al.1 re-examines the data regarding the role of sublobarresection for non-small cell lung cancer (NSCLC), a question that was “settled” 15
years ago by the Lung Cancer Study Group.2,3 Indeed, they are not alone, as a randomized
study re-examining this question is underway by the Cancer and Leukemia Group B
oncology group (140503). The level of interest suggests that many people suspect that the
answer regarding the role of sublobar resection has changed.
A closer look at the review by Blasberg et al., however, suggests that the real issue
is that with increased understanding, the questions have changed. The questions the
authors address are not simply whether sublobar resection is as good as lobectomy for
early-stage NSCLC. Rather, it is much more nuanced. First, they explore prognostic
factors in stage I NSCLC, especially size. Then, they review data regarding the technique
of sublobar resection (i.e., wedge resection versus segmentectomy). Specific subgroups of
NSCLC, namely bronchioloalveolar carcinoma, may be more amenable to sublobar
resection. Sophisticated methods of examining the margins may alter outcomes as well as
potentially the addition of brachytherapy.
It is important to be clear about what situations are being examined. First of all, it
is important to distinguish between a sublobar resection performed as a compromise in a
patient who is unable to tolerate a lobectomy from an elective sublobar resection
performed as an alternative to lobectomy. The former group has significant confounding
factors, such as competing causes of death. The issues are also different, involving how
one should define inability to tolerate lobectomy and the tradeoff between lower perioper-
ative mortality versus higher mortality from cancer. In my opinion, it is better to completely
separate these issues from those that are relevant with respect to elective sublobar resection and
not to mix results of one group with that of another in the same article.
If we take a more nuanced approach, it is important to be able to clearly see the
subtle differences in patients. This is an area that needs more research and clarity.
Potentially important factors are tumor size, the proportion of the lesion with ground glass
opacity (GGO) (i.e., pure GGO, 50% GGO, or mostly solid), the method of detection
(i.e., computed tomography screening, incidental computed tomography, or symptoms),
molecular or biochemical markers (i.e., epidermal growth factor receptor mutation and
carcinoembryonic antigen), rate of growth, and patient age. I don’t find the histologic
definition very useful clinically, because one cannot define a pure bronchioloalveolar
carcinoma (now called adenocarcinoma in situ) until the final pathology report on a
resected specimen is available. Unfortunately, these various factors are not clinically or
biologically independent, so we have some work to do to better understand what the most
important factors are and how we should develop an integrated way to define relevant
patient cohorts.
Blasberg et al. do not come to firm conclusions in their review, which is appropriate.
The available data, being primarily retrospective and with limited characterization of the
patient cohorts, does not allows firm conclusions to be drawn. However, it provides an
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important assessment of where we are in our understanding at
this time. This provides a useful current baseline as we
continue to explore the nuances with ongoing research.
Nevertheless, we are faced with new patients every day
and cannot postpone making decisions about how to approach
them and wait for the results of future studies. What is clear
from this review is that a sophisticated approach to use
sublobar resection is needed. Choosing the right patient
population, using the right technique (i.e., segmentectomy
with individual vessel/bronchial ligation), appropriately as-
sessing margins, etc., are all likely to significantly affect
outcomes. Some surgeons are clearly tempted to interpret the
interest and data regarding sublobar resection as justification
to use a simple thoracoscopic excision of a peripheral lesion
as a definitive cancer treatment. The detailed review by
Blasberg et al. clearly suggests that such a simplistic ap-
proach is not what the data addresses and cannot be endorsed.
Ideally, of course, we should be treating patients in the
context of clinical studies, such as the Cancer and Leukemia
Group B randomized trial. Second best is assembling a local
institutional team (i.e., surgeons, pulmonologists, and radiol-
ogists), reviewing the available data, and developing a formal
institutional policy. Making decisions on a case-by-case basis
based on one person’s judgment alone on a given day (i.e.,
without carefully thought out guiding principles) runs a high
risk that inappropriate management of many patients will
occur.
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